Global Congestive Heart Failure Drugs Market 2015-2019
About Congestive Heart Failure Drugs
Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged heart muscles are too weak to pump sufficient oxygen-rich blood to and from the body. ACE inhibitors/ARB antagonists, beta-adrenergic receptor blocking agents, diuretics, and inotropic drugs are the medications available for the treatment of congestive heart failure.
TechNavio's analysts forecast the Global Congestive Heart Failure Drugs market to grow at a CAGR of 9.47 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Congestive Heart Failure Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of approved drugs and generics used in the treatment of congestive heart failure that are available in the market. The Global Congestive Heart Failure Drugs market can be divided into four segments: ACE Inhibitors/ARB Antagonists, Beta-adrenergic Receptor Blocking Agents, Diuretics, and Inotropic Drugs/Vasodilators.
TechNavio's report, the Global Congestive Heart Failure Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Congestive Heart Failure Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
TechNavio Announces the Publication of its Research Report – Global Congestive Heart Failure Drugs Market 2015-2019
TechNavio recognizes the following companies as the key players in the Global Congestive Heart Failure Drugs Market: AstraZeneca plc, Bristol-Myers Squibb Co., GlaxoSmithKline plc (GSK), Merck & Co. Inc., Mylan Inc., Novartis AG, Pfizer Inc., Sanofi SA and Valeant Pharmaceuticals International Inc.
Other Prominent Vendors in the market are: Bayer, Bioheart, Boehringer Ingelheim, Takeda Pharmaceutical and Teva Pharmaceutical Industries.
Commenting on the report, an analyst from TechNavio’s team said: “One major trend witness in this market is the increase in awareness. The acceptability of congestive heart failure drugs is expected to increase because of the increase in public awareness. Patients and physicians are becoming more aware about congestive heart failure.”
According to the report, one of the main drivers of this market is the increase in the aging population. The elderly in both developing and developed countries have an increased risk of developing congestive heart failure and other ailments.
Further, the report states that one of the main challenges that the market faces is the weak drug pipeline. The market lacks promising pipeline molecules to address the unmet needs in the market. Therefore, new drugs in the pipeline will not have any effect on the growth of the market.
AstraZeneca, Bristol-Myers Squibb, GSK, Merck & Co., Mylan, Novartis, Pfizer, Sanofi, Valeant Pharmaceuticals, Bayer, Bioheart , Boehringer Inhelheim , Takeda Pharmaceutical , Teva Pharmaceutical Industries
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook